+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

BCG Vaccine Market by Demographics (Pediatric and Adults: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 165 Pages
  • February 2022
  • Region: Global
  • Allied Market Research
  • ID: 5578200
Description Jump to:
The global BCG vaccine market was valued at $46,637.5 thousands in 2020, and is projected to reach $74,269.55 thousands by 2030, registering a CAGR of 4.8% from 2021 to 2030.

Bacillus Calmette–Guérin (BCG) vaccine is the only vaccine available for the prevention of human forms of tuberculosis (TB). This vaccine is generally administered to children at birth in countries with high incidence of TB. In regions with low level of TB, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.

The global BCG vaccine market is driven by increase in prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, the increase in government initiatives and focus on immunization programs globally boost the market growth. However, side effects of BCG vaccine and the global shortage of BCG vaccine restrain this growth. Untapped market potential in developing regions are expected to present numerous opportunities for market development during the forecast period.

The BCG vaccine market is segmented on the basis of demographics, and region. On the basis of demographics, it is bifurcated into pediatrics (0-18 Years) and Adults (19-35 years). Region wise, the market is analyzed across Asia-Pacific, LAMEA, and Rest of the World.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans
  • A comprehensive analysis of the factors that drive and restrain the growth of the BCG vaccine market is provided
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves

KEY MARKET SEGMENTS


By Demographic Type

  • Pediatrics (0-18 Years)
  • Adults (19-35 Years)

By Region

  • Asia Pacific
  • India
  • China
  • Bangladesh
  • Pakistan
  • Indonesia
  • Japan
  • Thailand
  • Singapore
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Mexico
  • South Africa
  • Kenya
  • Argentina
  • Colombia
  • Chile
  • Rest of LAMEA
  • REST OF THE WORLD

KEY MARKET PLAYERS

  • AJ Biologics
  • China National group corporation (Sinopharm)
  • Greensignal Biopharma Limited
  • Intervax Ltd
  • Japan BCG Laboratory
  • Merck & Co, Inc
  • Sanofi
  • Serum Institute of India Pvt Ltd
  • Stetens Serum Institute
  • Torlak Institute of Virology

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
Chapter 4: Bcg Vaccine Market, by Demographics
4.1. Market Overview
4.1.1Market Size and Forecast, by Demographics
4.2. Pediatrics (Age 0-18 Years)
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.3. Adults (Age 19-35 Years)
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
Chapter 5: Bcg Vaccine Market, by Region
5.1. Market Overview
5.1.1Market Size and Forecast, by Region
5.2. Asia-Pacific
5.2.1. Key Market Trends and Opportunities
5.2.2. Market Size and Forecast, by Demographics
5.2.3. Market Size and Forecast, by Country
5.2.4. India Bcg Vaccine Market
5.2.4.1. Market Size and Forecast, by Demographics
5.2.5. China Bcg Vaccine Market
5.2.5.1. Market Size and Forecast, by Demographics
5.2.6. Bangladesh Bcg Vaccine Market
5.2.6.1. Market Size and Forecast, by Demographics
5.2.7. Pakistan Bcg Vaccine Market
5.2.7.1. Market Size and Forecast, by Demographics
5.2.8. Indonesia Bcg Vaccine Market
5.2.8.1. Market Size and Forecast, by Demographics
5.2.9. Japan Bcg Vaccine Market
5.2.9.1. Market Size and Forecast, by Demographics
5.2.10. Thailand Bcg Vaccine Market
5.2.10.1. Market Size and Forecast, by Demographics
5.2.11. Singapore Bcg Vaccine Market
5.2.11.1. Market Size and Forecast, by Demographics
5.2.12. Rest of Asia-Pacific Bcg Vaccine Market
5.2.12.1. Market Size and Forecast, by Demographics
5.3. Lamea
5.3.1. Key Market Trends and Opportunities
5.3.2. Market Size and Forecast, by Demographics
5.3.3. Market Size and Forecast, by Country
5.3.4. Brazil Bcg Vaccine Market
5.3.4.1. Market Size and Forecast, by Demographics
5.3.5. Mexico Bcg Vaccine Market
5.3.5.1. Market Size and Forecast, by Demographics
5.3.6. South Africa Bcg Vaccine Market
5.3.6.1. Market Size and Forecast, by Demographics
5.3.7. Kenya Bcg Vaccine Market
5.3.7.1. Market Size and Forecast, by Demographics
5.3.8. Argentina Bcg Vaccine Market
5.3.8.1. Market Size and Forecast, by Demographics
5.3.9. Colombia Bcg Vaccine Market
5.3.9.1. Market Size and Forecast, by Demographics
5.3.10. Chile Bcg Vaccine Market
5.3.10.1. Market Size and Forecast, by Demographics
5.3.11. Rest of LAMEA Bcg Vaccine Market
5.3.11.1. Market Size and Forecast, by Demographics
5.4. Rest of the World
5.4.1. Key Market Trends and Opportunities
5.4.2. Market Size and Forecast, by Demographics
Chapter 6: Company Profiles
6.1. Aj Biologics
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Company Snapshot
6.1.4. Operating Business Segments
6.1.5. Product Portfolio
6.1.6. Business Performance
6.1.7. Key Strategic Moves and Developments
6.2. China National Group Corporation (Sinopharm)
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Company Snapshot
6.2.4. Operating Business Segments
6.2.5. Product Portfolio
6.2.6. Business Performance
6.2.7. Key Strategic Moves and Developments
6.3. Greensignal Biopharma Limited
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Company Snapshot
6.3.4. Operating Business Segments
6.3.5. Product Portfolio
6.3.6. Business Performance
6.3.7. Key Strategic Moves and Developments
6.4. Intervax Ltd.
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Company Snapshot
6.4.4. Operating Business Segments
6.4.5. Product Portfolio
6.4.6. Business Performance
6.4.7. Key Strategic Moves and Developments
6.5. Japan Bcg Laboratory
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Company Snapshot
6.5.4. Operating Business Segments
6.5.5. Product Portfolio
6.5.6. Business Performance
6.5.7. Key Strategic Moves and Developments
6.6. Merck and Co. Inc.
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Company Snapshot
6.6.4. Operating Business Segments
6.6.5. Product Portfolio
6.6.6. Business Performance
6.6.7. Key Strategic Moves and Developments
6.7. Sanofi
6.7.1. Company Overview
6.7.2. Key Executives
6.7.3. Company Snapshot
6.7.4. Operating Business Segments
6.7.5. Product Portfolio
6.7.6. Business Performance
6.7.7. Key Strategic Moves and Developments
6.8. Serum Institute of India Pvt. Ltd.
6.8.1. Company Overview
6.8.2. Key Executives
6.8.3. Company Snapshot
6.8.4. Operating Business Segments
6.8.5. Product Portfolio
6.8.6. Business Performance
6.8.7. Key Strategic Moves and Developments
6.9. Stetens Serum Institute
6.9.1. Company Overview
6.9.2. Key Executives
6.9.3. Company Snapshot
6.9.4. Operating Business Segments
6.9.5. Product Portfolio
6.9.6. Business Performance
6.9.7. Key Strategic Moves and Developments
6.10. Torlak Institute of Virology
6.10.1. Company Overview
6.10.2. Key Executives
6.10.3. Company Snapshot
6.10.4. Operating Business Segments
6.10.5. Product Portfolio
6.10.6. Business Performance
6.10.7. Key Strategic Moves and Developments
List of Tables
Table 1. Global Bcg Vaccine Market, by Demographics, 2020-2030 ($Million)
Table 2. Global Bcg Vaccine Market for Pediatrics (Age 0-18 Years), by Region, 2020-2030 ($Million)
Table 3. Global Bcg Vaccine Market for Adults (Age 19-35 Years), by Region, 2020-2030 ($Million)
Table 4. Global Bcg Vaccine Market, by Region, 2020-2030 ($Million)
Table 5. Asia-Pacific Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 6. India Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 7. China Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 8. Bangladesh Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 9. Pakistan Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 10. Indonesia Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 11. Japan Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 12. Thailand Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 13. Singapore Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 14. Rest of Asia-Pacific Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 15. Lamea Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 16. Brazil Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 17. Mexico Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 18. South Africa Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 19. Kenya Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 20. Argentina Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 21. Colombia Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 22. Chile Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 23. Rest of LAMEA Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 24. Rest of the World Bcg Vaccine, by Demographics, 2020-2030 ($Million)
Table 25. Aj Biologics: Key Executives
Table 26. Aj Biologics: Company Snapshot
Table 27. Aj Biologics: Operating Segments
Table 28. Aj Biologics: Product Portfolio
Table 29. Aj Biologics: Key Strategic Moves and Developments
Table 30. China National Group Corporation (Sinopharm): Key Executives
Table 31. China National Group Corporation (Sinopharm): Company Snapshot
Table 32. China National Group Corporation (Sinopharm): Operating Segments
Table 33. China National Group Corporation (Sinopharm): Product Portfolio
Table 34. China National Group Corporation (Sinopharm): Key Strategic Moves and Developments
Table 35. Greensignal Biopharma Limited: Key Executives
Table 36. Greensignal Biopharma Limited: Company Snapshot
Table 37. Greensignal Biopharma Limited: Operating Segments
Table 38. Greensignal Biopharma Limited: Product Portfolio
Table 39. Greensignal Biopharma Limited: Key Strategic Moves and Developments
Table 40. Intervax Ltd. : Key Executives
Table 41. Intervax Ltd. : Company Snapshot
Table 42. Intervax Ltd. : Operating Segments
Table 43. Intervax Ltd. : Product Portfolio
Table 44. Intervax Ltd. : Key Strategic Moves and Developments
Table 45. Japan Bcg Laboratory: Key Executives
Table 46. Japan Bcg Laboratory: Company Snapshot
Table 47. Japan Bcg Laboratory: Operating Segments
Table 48. Japan Bcg Laboratory: Product Portfolio
Table 49. Japan Bcg Laboratory: Key Strategic Moves and Developments
Table 50. Merck and Co. Inc. : Key Executives
Table 51. Merck and Co. Inc. : Company Snapshot
Table 52. Merck and Co. Inc. : Operating Segments
Table 53. Merck and Co. Inc. : Product Portfolio
Table 54. Merck and Co. Inc. : Key Strategic Moves and Developments
Table 55. Sanofi: Key Executives
Table 56. Sanofi: Company Snapshot
Table 57. Sanofi: Operating Segments
Table 58. Sanofi: Product Portfolio
Table 59. Sanofi: Key Strategic Moves and Developments
Table 60. Serum Institute of India Pvt. Ltd. : Key Executives
Table 61. Serum Institute of India Pvt. Ltd. : Company Snapshot
Table 62. Serum Institute of India Pvt. Ltd. : Operating Segments
Table 63. Serum Institute of India Pvt. Ltd. : Product Portfolio
Table 64. Serum Institute of India Pvt. Ltd. : Key Strategic Moves and Developments
Table 65. Stetens Serum Institute: Key Executives
Table 66. Stetens Serum Institute: Company Snapshot
Table 67. Stetens Serum Institute: Operating Segments
Table 68. Stetens Serum Institute: Product Portfolio
Table 69. Stetens Serum Institute: Key Strategic Moves and Developments
Table 70. Torlak Institute of Virology: Key Executives
Table 71. Torlak Institute of Virology: Company Snapshot
Table 72. Torlak Institute of Virology: Operating Segments
Table 73. Torlak Institute of Virology: Product Portfolio
Table 74. Torlak Institute of Virology: Key Strategic Moves and Developments
List of Figures
Figure 1. Global Bcg Vaccine Market Segmentation
Figure 2. Global Bcg Vaccine Market
Figure 3. Segmentation Bcg Vaccine Market
Figure 4. Top Investment Pocket in Bcg Vaccine Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Bcg Vaccine Market
Figure 16. Bcg Vaccine Market Segmentation, by Demographics
Figure 17. Bcg Vaccine Market for Pediatrics (Age 0-18 Years), by Country, 2020-2030 ($ Million)
Figure 18. Bcg Vaccine Market for Adults (Age 19-35 Years), by Country, 2020-2030 ($ Million)
Figure 19. Aj Biologics: Net Sales, 2018-2020 ($ Million)
Figure 20. Aj Biologics: Revenue Share, by Segment, 2020 (%)
Figure 21. Aj Biologics: Revenue Share, by Region, 2020 (%)
Figure 22. China National Group Corporation (Sinopharm): Net Sales, 2018-2020 ($ Million)
Figure 23. China National Group Corporation (Sinopharm): Revenue Share, by Segment, 2020 (%)
Figure 24. China National Group Corporation (Sinopharm): Revenue Share, by Region, 2020 (%)
Figure 25. Greensignal Biopharma Limited: Net Sales, 2018-2020 ($ Million)
Figure 26. Greensignal Biopharma Limited: Revenue Share, by Segment, 2020 (%)
Figure 27. Greensignal Biopharma Limited: Revenue Share, by Region, 2020 (%)
Figure 28. Intervax Ltd: Net Sales, 2018-2020 ($ Million)
Figure 29. Intervax Ltd: Revenue Share, by Segment, 2020 (%)
Figure 30. Intervax Ltd: Revenue Share, by Region, 2020 (%)
Figure 31. Japan Bcg Laboratory: Net Sales, 2018-2020 ($ Million)
Figure 32. Japan Bcg Laboratory: Revenue Share, by Segment, 2020 (%)
Figure 33. Japan Bcg Laboratory: Revenue Share, by Region, 2020 (%)
Figure 34. Merck and Co. Inc: Net Sales, 2018-2020 ($ Million)
Figure 35. Merck and Co. Inc: Revenue Share, by Segment, 2020 (%)
Figure 36. Merck and Co. Inc: Revenue Share, by Region, 2020 (%)
Figure 37. Sanofi: Net Sales, 2018-2020 ($ Million)
Figure 38. Sanofi: Revenue Share, by Segment, 2020 (%)
Figure 39. Sanofi: Revenue Share, by Region, 2020 (%)
Figure 40. Serum Institute of India Pvt. Ltd: Net Sales, 2018-2020 ($ Million)
Figure 41. Serum Institute of India Pvt. Ltd: Revenue Share, by Segment, 2020 (%)
Figure 42. Serum Institute of India Pvt. Ltd: Revenue Share, by Region, 2020 (%)
Figure 43. Stetens Serum Institute: Net Sales, 2018-2020 ($ Million)
Figure 44. Stetens Serum Institute: Revenue Share, by Segment, 2020 (%)
Figure 45. Stetens Serum Institute: Revenue Share, by Region, 2020 (%)
Figure 46. Torlak Institute of Virology: Net Sales, 2018-2020 ($ Million)
Figure 47. Torlak Institute of Virology: Revenue Share, by Segment, 2020 (%)
Figure 48. Torlak Institute of Virology: Revenue Share, by Region, 2020 (%)

Executive Summary

According to a new report titled, “BCG Vaccine Market by Demographics: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global BCG Vaccine market was valued at $46,637.5 thousands in 2020, and is projected to reach $74,269.55 thousands by 2030, registering a CAGR of 4.8% from 2021 to 2030.

Bacillus Calmette–Guérin (BCG) vaccine is the only vaccine currently available for the prevention of tuberculosis (TB). One dose of BCG vaccine is recommended for healthy babies at birth in countries where tuberculosis is common.

The growth of the BCG vaccine market is driven by increase in incidence rate of tuberculosis in developing nations, rise in R&D activities related to vaccines, growth in government initiatives, and focus on immunization programs globally. However, side reactions of BCG vaccines on patients and shortage of vaccine supply hinder the market growth. Moreover, untapped market opportunities in developing regions are expected to provide numerous opportunities for market growth during the forecast period.

As there is no current alternative to BCG vaccine, therefore there is an urgent need to improve the methods used for quality control of BCG. This is possible with the help of technological advancements in the field of genomics and proteomics, which help in development of new methods for BCG testing. These advanced testing methods can ensure the safety, quality, and efficacy of BCG vaccine preparations.

Coronavirus (COVID-19) was discovered in late December, 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. The outbreak of COVID-19 pandemic has not affected the BCG vaccine market as BCG vaccination among pediatric population has not decreased. Moreover, BCG vaccination decreases susceptibility to respiratory tract infections and improves immunity in pediatrics. Moreover, few countries underwent some clinical trials on humans to see the effectiveness of BCG vaccine towards COVID-19, which boosts the BCG vaccine market growth. These all factors show positive impact of COVID-19 on the BCG vaccine market. Thus, the COVID-19 pandemic has a positive impact on the BCG vaccine market.

The BCG vaccine market is segmented on the basis of demographics, and region. On the basis of demographics, it is bifurcated into pediatrics (0-18 Years) and adults (19-35 years). Region wise, the market is analyzed across Asia-Pacific, LAMEA, and Rest of the World.

Based on demographics, the pediatrics (0-18 Years) segment is expected to maintain its dominant position during the forecast period, as the vaccine is administered to all the children at the time of birth. As BCG is recommended for only one dose; therefore, it is used rarely in the case of adults.

Rest of the World accounted for major share of the global BCG vaccine market in 2020, and is expected to remain dominant during the forecast period. This was attributed to increase in prevalence of tuberculosis, rise in number of immunization programs, availability of advanced healthcare facilities with trained medical professionals, presence of most of the key players, and surge in investment made by governments in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare.

Key Findings Of Study


  • On the basis of demographics, the pediatrics (0-18 Years) segment held the largest market share in 2020 and is expected to remain dominant during the forecast period
  • Region-wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 53% during the forecast period

Companies Mentioned

  • AJ Biologics
  • China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation)
  • Merck & Co., Inc.
  • Sanofi Pasteur
  • Japan BCG Laboratory
  • Serum Institute of India Pvt. Ltd.
  • InterVax Ltd.
  • GreenSignal Bio Pharma Limited (GSBPL)
  • Statens Serum Institut
  • Torlak Institute of Virology.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Therapeutic BCG Vaccine Market by Type, Demographics, End User - Global Forecast 2025-2030 - Product Image

Therapeutic BCG Vaccine Market by Type, Demographics, End User - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
BCG Vaccine Market by Age Group, Application, Distribution Channel, and By Region - Product Image

BCG Vaccine Market by Age Group, Application, Distribution Channel, and By Region

  • Report
  • 200 Pages
  • Global
From
BCG Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology - Product Image

BCG Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology

  • Report
  • 96 Pages
  • Global
From
The World Market for Vaccines, 2024 - Product Image

The World Market for Vaccines, 2024

  • Report
  • 202 Pages
  • Global
From
Vaccines Markets in China - Product Image

Vaccines Markets in China

  • Report
  • 326 Pages
  • China
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.